Risperidone in Children with Autism and Serious Behavioral Problems
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Atypical antipsychotic agents, which block postsynaptic dopamine and serotonin receptors, have advantages over traditional antipsychotic medications in the treatment of adults with schizophrenia and may be beneficial in children with autistic disorder who have serious behavioral disturbances. However, data on the safety and efficacy of atypical antipsychotic agents in children are limited. METHODS: We conducted a multisite, randomized, double-blind trial of risperidone as compared with placebo for the treatment of autistic disorder accompanied by severe tantrums, aggression, or self-injurious behavior in children 5 to 17 years old. The primary outcome measures were the score on the Irritability subscale of the Aberrant Behavior Checklist and the rating on the Clinical Global Impressions - Improvement (CGI-I) scale at eight weeks. RESULTS: A total of 101 children (82 boys and 19 girls; mean [+/-SD] age, 8.8+/-2.7 years) were randomly assigned to receive risperidone (49 children) or placebo (52). Treatment with risperidone for eight weeks (dose range, 0.5 to 3.5 mg per day) resulted in a 56.9 percent reduction in the Irritability score, as compared with a 14.1 percent decrease in the placebo group (P<0.001). The rate of a positive response, defined as at least a 25 percent decrease in the Irritability score and a rating of much improved or very much improved on the CGI-I scale, was 69 percent in the risperidone group (34 of 49 children had a positive response) and 12 percent in the placebo group (6 of 52, P<0.001). Risperidone therapy was associated with an average weight gain of 2.7+/-2.9 kg, as compared with 0.8+/-2.2 kg with placebo (P<0.001). Increased appetite, fatigue, drowsiness, dizziness, and drooling were more common in the risperidone group than in the placebo group (P<0.05 for each comparison). In two thirds of the children with a positive response to risperidone at eight weeks (23 of 34), the benefit was maintained at six months. CONCLUSIONS: Risperidone was effective and well tolerated for the treatment of tantrums, aggression, or self-injurious behavior in children with autistic disorder. The short period of this trial limits inferences about adverse effects such as tardive dyskinesia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Methylphenidate, atomoxetine and guanfacine are beneficial for ADHD symptoms in ASD (Table 2 204 -206 )”
From Autism spectrum disorder (2020) · cites this paper as [206]
In the citing paper
“Currently, only two drugs have been approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the ASD population: risperidone [23] and aripiprazole [24]. Both drugs are approved for the treatment of irritability in children and adolescents with ASD.”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“as the two drugs that have received FDA approval for use in ASD, risperidone, and aripiprazole, are both for the indication of “irritability” [23, 24]”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“risperidone and aripiprazole, which are both FDA-approved for irritability in children and adolescents with ASD [23, 24].”
From Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms (2025) · cites this paper as [23]
In the citing paper
“and significant improvement in core autism symptoms [601-604].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [601]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Littell, R. C. (1996) · Medical Entomology and Zoology · Cited by 10,547
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS
SIMPSON, G. M., B., M., B., G., ANGUS, J. W. S., P., F. R. C., & M., D. P. (1970) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1970.tb02066.x · Cited by 3,264
ECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Kapur, S., & Seeman, P. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.3.360 · Cited by 1,140
Pervasive Developmental Disorders in preschool children
Chakrabarti, S. (2001) · JAMA · doi:10.1001/jama.285.24.3093 · Cited by 1,132
Gibbons, R. D. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210073009 · Cited by 719
McDougle, C. J., Holmes, J. P., Carlson, D. C., Pelton, G. H., Cohen, D. J., & Price, L. H. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.7.633 · Cited by 427
Self-citationDiagnosing Autism: Analyses of Data from the Autism Diagnostic Interview
Lord, C., Pickles, A., McLennan, J., Rutter, M., Bregman, J., Folstein, S., Fombonne, E., Leboyer, M., & Minshew, N. (1997) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1025873925661 · Cited by 373
The Vineland Adaptive Behavior Scales: Supplementary Norms for Individuals with Autism
Carter, A. S., Volkmar, F. R., Sparrow, S. S., Wang, J.-J., Lord, C., Dawson, G., Fombonne, E., Loveland, K., Mesibov, G., & Schopler, E. (1998) · Journal of Autism and Developmental Disorders · doi:10.1023/a:1026056518470 · Cited by 367
Self-citation
Cited by
Items 301–400 of 1,000
Dai, Y., Zhang, H., Schön, M., Böckers, T. M., Han, S., Han, J., & Zhang, R. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00355 · Cited by 96
Matheson, B. E., & Douglas, J. M. (2017) · Review Journal of Autism and Developmental Disorders · doi:10.1007/s40489-017-0103-7 · Cited by 81
Valicenti-McDermott, M. R., & Demb, H. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.549 · Cited by 82
Template to Perpetrate: An Update on Violence in Autism Spectrum Disorder
Im, D. S. (2016) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000087 · Cited by 81
Stivaros, S. M., Garg, S., Tziraki, M., Cai, Y., Thomas, O., Mellor, J., Morris, A. A. M., Jim, C., Szumanska-Ryt, K., Parkes, L. M., et al. (2018) · Molecular Autism · doi:10.1186/s13229-018-0190-z · Cited by 86
“Following standard practice in autism medication trials [36], clinical responders were Stivaros et al.”
MethodCognitive Effects of Risperidone in Children with Autism and Irritable Behavior
Aman, M. G., Hollway, J. A., McDougle, C. J., Scahill, L., Tierney, E., McCracken, J. T., Arnold, L. E., Vitiello, B., Ritz, L., Gavaletz, A., et al. (2008) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0133 · Cited by 80
Self-citationMicronutrients Versus Standard Medication Management in Autism: A Naturalistic Case–Control Study
Mehl-Madrona, L., Leung, B., Kennedy, C., Paul, S., & Kaplan, B. J. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0011 · Cited by 79
“Although they do not carry the weight of an RCT, case–control studies with heterogeneous patients from medical practice can be instructive about whether or not particular approaches are promising.”
InfluentialSchubart, J. R., Camacho, F., & Leslie, D. (2014) · Autism · doi:10.1177/1362361313497537 · Cited by 80
“Although only risperidone and aripiprazole (both atypical antipsychotics) have been approved by the Food and Drug Administration for treatment of aggression and irritability in ASD, many medications are commonly prescribed (Ching and Pringshei, 2012; McCracken et al., 2002; Posey et al., 2008).”
BackgroundOverweight and obese status in children with autism spectrum disorder and disruptive behavior
Criado, K. K., Sharp, W. G., McCracken, C. E., De Vinck-Baroody, O., Dong, L., Aman, M. G., McDougle, C. J., McCracken, J. T., Eugene Arnold, L., Weitzman, C., et al. (2018) · Autism · doi:10.1177/1362361316683888 · Cited by 78
Self-citationPsychopharmacology in autism: an update
Canitano, R., & Scandurra, V. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.10.015 · Cited by 79
Autism: an emerging ‘neuroimmune disorder’ in search of therapy
Theoharides, T. C., Kempuraj, D., & Redwood, L. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903107789 · Cited by 79
“Risperidone Dopamine receptor antagonist Aggression ↓ Irritability ↓ Weight ↑ [183-185]”
BackgroundAmodeo, D. A., Jones, J. H., Sweeney, J. A., & Ragozzino, M. E. (2014) · Autism Research · doi:10.1002/aur.1395 · Cited by 79
Masi, A., Lampit, A., Glozier, N., Hickie, I. B., & Guastella, A. J. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.143 · Cited by 78
“Random McCracken et al. 2002 (34) 0.35 (0.14 to 0.57) 5.26 Shea et al. 2004 (35) 0.62 (0.36 to 0.88) 4.75 Hellings et al. 2005 (3) 0.73 (0.29 to 1.17) 3.12 Hollander et al. 2005 (2) 0.62 (0.24 to 0.99) 3.64 Nagaraj et al. 2006 (51) 0.32 (–0.02 to 0.65) 4.01 Akhondzadeh et al. 2008 (48) 0.59 (0.23…”
InfluentialGadow, K. D., Arnold, L. E., Molina, B. S. G., Findling, R. L., Bukstein, O. G., Brown, N. V., McNamara, N., Rundberg-Rivera, E. V., Li, X., Kipp, H., et al. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2014.05.008 · Cited by 80
Self-citationCarlson, G. A., Jensen, P. S., Findling, R. L., Meyer, R. E., Calabrese, J., DelBello, M. P., Emslie, G., Flynn, L., Goodwin, F., Hellander, M., et al. (2003) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/104454603321666162 · Cited by 79
“The Overt Aggression Scale-Modified (Coccaro et al., 1991) has been used in several multisite studies of aggression (e.g., McCracken et al., 2002).”
Self-citationReview of Safety Assessment Methods Used in Pediatric Psychopharmacology
Greenhill, L. L., Shockey, E. M., Davies, M., Fisher, P. W., Fried, J. E., Capasso, L., ROSENGARTEN, J., Vitiello, B., Riddle, M. A., VARIPATIS, E., et al. (2003) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/01.chi.0000046841.56865.37 · Cited by 81
Self-citationSiafis, S., Çıray, R. O., Schneider‐Thoma, J., Bighelli, I., Krause, M., Rodolico, A., Ceraso, A., Deste, G., Huhn, M., Fraguas, D., et al. (2020) · Molecular Autism · doi:10.1186/s13229-020-00372-z · Cited by 80
“…and the other outcomes (no reply from the corresponding author), in Saad 2015, CARS was rated by caregivers but it was unclear if also filled by clinicians (no reply from the corresponding author), as well as in RUPP 2002 and Handen 2012 the Ritvo-Freeman Life Rating Scale was rated by caregivers.”
BackgroundManagement of hyperactivity and other acting-out problems in patients with autism spectrum disorder
Aman, M. G. (2004) · Seminars in Pediatric Neurology · doi:10.1016/j.spen.2004.07.006 · Cited by 86
Self-citationWink, L. K., Early, M., Schaefer, T., Pottenger, A., Horn, P., McDougle, C. J., & Erickson, C. A. (2014) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2013.0099 · Cited by 76
“…antipsychotic naive children and adolescents with a variety of psychiatric diagnoses (Correll et al. 2009), and short-term data from autism trials (McCracken et al. 2002; Martin et al. 2004; Shea et al. 2004; Marcus et al. 2011), we hypothesized that risperidone use would be associated with a…”
InfluentialSelf-citationJanowsky, D. S., Kraus, J. E., Barnhill, J., Elamir, B., & Davis, J. M. (2003) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000088906.24613.76 · Cited by 76
“More recently, newer atypical antipsychotic agents have also been used.(1,2) However, conventional antipsychotic agents carry the risk of development of extrapyramidal symptoms and tardive dyskinesia.”
BackgroundPharmacogenetics of antipsychotic-induced weight gain
Müller, D., Muglia, P., Fortune, T., & Kennedy, J. L. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.05.001 · Cited by 89
Three autism candidate genes: a synthesis of human genetic analysis with other disciplines
Bartlett, C. W., Gharani, N., Millonig, J. H., & Brzustowicz, L. M. (2005) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2004.10.004 · Cited by 75
“Instead, only some of the autistic anatomical phenotypes like cerebellar hypoplasia might be observed.”
BackgroundInfluentialScahill, L., Aman, M. G., McDougle, C. J., Arnold, L. E., McCracken, J. T., Handen, B., Johnson, C., Dziura, J., Butter, E., Sukhodolsky, D., et al. (2009) · Journal of Autism and Developmental Disorders · doi:10.1007/s10803-008-0675-2 · Cited by 75
Self-citationAnterior cingulate volume in pediatric bipolar disorder and autism
Chiu, S., Widjaja, F., Bates, M. E., Voelbel, G. T., Pandina, G., Marble, J., Blank, J., Day, J., Brule, N., & Hendren, R. L. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.04.019 · Cited by 77
Pharmacological Treatment Options for Autism Spectrum Disorders in Children and Adolescents
Leskovec, T. J., Rowles, B. M., & Findling, R. L. (2008) · Harvard Review of Psychiatry · doi:10.1080/10673220802075852 · Cited by 89
Murphy, T. K., Fernandez, T. V., Coffey, B. J., Rahman, O., Gavaletz, A., Hanks, C. E., Tillberg, C. S., Ibanez-Gomez, L., Sukhodolsky, D. G., Katsovich, L., et al. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0024 · Cited by 80
Self-citationRisperidone in Children with Autism and Serious Behavioral Problems
Munarriz, R. M., Bennett, L., & Goldstein, I. (2002) · New England Journal of Medicine · doi:10.1056/nejm200212053472316 · Cited by 75
Canitano, R. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s1450 · Cited by 74
Toward an exportable parent training program for disruptive behaviors in autism spectrum disorder
Bearss, K., Lecavalier, L., Minshawi, N., Johnson, C., Smith, T., Handen, B., Sukhodolsky, D. G., Aman, M. G., Swiezy, N., Butter, E., et al. (2013) · Neuropsychiatry · doi:10.2217/npy.13.14 · Cited by 74
Self-citationManagement of Agitation in Individuals with Autism Spectrum Disorders in the Emergency Department
McGonigle, J. J., Venkat, A., Beresford, C. A., Campbell, T. P., & Gabriels, R. L. (2013) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2013.08.003 · Cited by 77
Higashida, H., Yokoyama, S., Huang, J.-J., Liu, L., Ma, W.-J., Akther, S., Higashida, C., Kikuchi, M., Minabe, Y., & Munesue, T. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.01.030 · Cited by 73
“For example, risperidone, a 18 second-generation antipsychotic, was suggested to be effective in managing irritability such as tantrums, aggression, and self-injurious behavior in ASD subjects, but not social withdrawal and inappropriate speech (McCracken et al., 2002).”
Scahill, L., Dimitropoulos, A., McDougle, C. J., Aman, M. G., Feurer, I. D., McCracken, J. T., Tierney, E., Pu, J., White, S., Lecavalier, L., et al. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.09.018 · Cited by 75
Self-citationPaliperidone for irritability in adolescents and young adults with autistic disorder
Stigler, K. A., Mullett, J. E., Erickson, C. A., Posey, D. J., & McDougle, C. J. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2711-3 · Cited by 76
Self-citationCarroll, D., Hallett, V., McDougle, C. J., Aman, M. G., McCracken, J. T., Tierney, E., Arnold, L. E., Sukhodolsky, D. G., Lecavalier, L., Handen, B. L., et al. (2013) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2013.08.002 · Cited by 80
Self-citationMandell, D. S. (2012) · Archives of Pediatrics & Adolescent Medicine · doi:10.1001/archpediatrics.2011.714 · Cited by 73
The effect of antidepressants and antipsychotics on weight gain in children and adolescents
Reekie, J., Hosking, S. P. M., Prakash, C., Kao, K. ‐., Juonala, M., & Sabin, M. A. (2015) · Obesity Reviews · doi:10.1111/obr.12284 · Cited by 72
“(46) reported that the weight gain in the risperidone group was associated with a significant increase in appetite, as reported by the parent or primary caretaker.”
BackgroundEarly Onset Bipolar Disorder: Clinical and Research Considerations
Carlson, G. A. (2005) · Journal of Clinical Child & Adolescent Psychology · doi:10.1207/s15374424jccp3402_13 · Cited by 79
“His anxiety and social awkwardness appear to have diminished with an atypical antipsychotic, a class of medication that has demonstrated utility in schizophrenia, mania, autism, and conduct disorder (Kowatch & DelBello, 2003; McCracken et al., 2002; Schur et al., 2003).”
BackgroundRisperidone for children and adolescents with autism spectrum disorder: a systematic review
Maneeton, N., Maneeton, B., Putthisri, S., Woottiluk, P., Narkpongphun, A., & Srisurapanont, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s151802 · Cited by 85
“Furthermore, the evidence from RCTs has illustrated its efficacy in symptomatic treatment for behavioral problems such as irritability, aggression, self-injurious behavior and tantrums in children and adolescents with ASD having the short-term treatment with well tolerability.(12,15,16) In addition, a previous review…”
Selective Mutism and Its Relations to Social Anxiety Disorder and Autism Spectrum Disorder
Muris, P., & Ollendick, T. H. (2021) · Clinical Child and Family Psychology Review · doi:10.1007/s10567-020-00342-0 · Cited by 93
Psychopharmacological Interventions in Autism Spectrum Disorder
Politte, L. C., Henry, C. A., & McDougle, C. J. (2014) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000030 · Cited by 71
“In 2002, the RUPP Autism Network published results of a multisite, controlled trial of risperidone in children with autism and severe behavioral disturbance (n = 101; age range, 5–17 years) that included an eight-week active treatment phase followed by a fourmonth open-label continuation phase and two-month discontinu…”
Self-citationDevelopmental Disabilities Modification of the Children’s Global Assessment Scale
Wagner, A., Lecavalier, L., Arnold, L. E., Aman, M. G., Scahill, L. D., Stigler, K. A., Johnson, C. R., McDougle, C. J., & Vitiello, B. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.001 · Cited by 84
Self-citationMinshawi, N. F., Wink, L. K., Shaffer, R., Plawecki, M. H., Posey, D. J., Liu, H., Hurwitz, S., McDougle, C. J., Swiezy, N. B., & Erickson, C. A. (2016) · Molecular Autism · doi:10.1186/s13229-015-0062-8 · Cited by 73
“The ABC has been extensively used in psychopharmacological studies of ASD [42].”
MethodSelf-citationBangerter, A., Ness, S. L., Aman, M. G., Esbensen, A. J., Goodwin, M. S., Dawson, G., Hendren, R. L., LEVENTHAL, B. L., Khan, A., Opler, M. G. A., et al. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0018 · Cited by 84
“Other instruments frequently used as clinical trials endpoints (McCracken et al. 2002; Research Units on Pediatric Psychopharmacology Autism Network 2005; Akhondzadeh et al. 2008; King et al. 2009; Marcus et al. 2009, 2011; Scahill et al. 2012; Singh et al. 2014) include the Repetitive Behavior…”
Self-citationMartínez-Ortega, J. M., Funes-Godoy, S., Díaz-Atienza, F., Gutiérrez-Rojas, L., Pérez-Costillas, L., & Gurpegui, M. (2013) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-013-0399-5 · Cited by 80
Clinical trials in autism spectrum disorder: evidence, challenges and future directions
Anagnostou, E. (2018) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000542 · Cited by 72
Placebo effects in developmental disabilities: Implications for research and practice
Sandler, A. (2005) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20065 · Cited by 72
Neurodevelopmental Behavioral and Cognitive Disorders
Jeste, S. (2015) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000466661.89908.3c · Cited by 90
“The only FDA-approved medications for autism spectrum disorder are the atypical antipsychotics, risperidone and aripiprazole, both of which are approved for the treatment of irritability, defined by physical aggression and tantrum behavior.(46,47) Their primary, sometimes doselimiting, side effects include weight gain…”
BackgroundImmunological Dysfunction in Autism Spectrum Disorder: A Potential Target for Therapy
Marchezan, J., Winkler dos Santos, E. G. A., Deckmann, I., & Riesgo, R. D. S. (2018) · Neuroimmunomodulation · doi:10.1159/000492225 · Cited by 70
Panagiotopoulos, C., Ronsley, R. J., Elbe, D., Davidson, J., & Smith, D. H. (2010) · Europe PMC (PubMed Central) · Cited by 88
King, B. H., Dukes, K., Donnelly, C. L., Sikich, L., McCracken, J. T., Scahill, L., Hollander, E., Bregman, J. D., Anagnostou, E., Robinson, F., et al. (2013) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2013.2698 · Cited by 67
Self-citationBeherec, L., Lambrey, S., Quilici, G., Rosier, A., Falissard, B., & Guillin, O. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318218f4a1 · Cited by 81
Metabolic side effects of atypical antipsychotics in children: a literature review
Fedorowicz, V. J., & Fombonne, E. J. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105056543 · Cited by 81
“The best evidence comes from two large DBRCTs (Aman et al., 2002; McCracken et al., 2002) in which risperidone was associated with significantly greater weight gain than placebo.”
BackgroundTrends in Psychiatry and Psychotherapy
(2020) · Trends in Psychiatry and Psychotherapy · doi:10.47626/2237-6089 · Cited by 70
Drug therapy for attention-deficit/hyperactivity disorder-like symptoms in autistic disorder
Hazell, P. (2007) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2007.00995.x · Cited by 69
A prospective open-label study of aripiprazole in fragile X syndrome
Erickson, C. A., Stigler, K. A., Wink, L. K., Mullett, J. E., Kohn, A., Posey, D. J., & McDougle, C. J. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2194-7 · Cited by 69
Self-citationFrazier, T. W., Youngstrom, E. A., Haycook, T., Sinoff, A., Dimitriou, F., Knapp, J., & Sinclair, L. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2009.0048 · Cited by 70
“…the use of typical and atypical antipsychotic medications in the treatment of aggressive behavior in ASD (Anderson et al. 1984; Horrigan and Barnhill 1997; Posey et al. 1999; Vercellino et al. 2001; McCracken et al. 2002; Accardo 2003; Kratochvil et al. 2005; McDougle et al. 2005; Canitano 2006).”
InfluentialThe status of pharmacotherapy for autism spectrum disorders
Myers, S. M. (2007) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.8.11.1579 · Cited by 69
“Aggression, explosive outbursts, self-injury, irritability Atypical antipsychotic (risperidone*, aripiprazole, olanzapine, quetiapine, ziprasidone) [50-57,60,70-79,83,84,86-88]”
BackgroundInfluentialTillman, R., Geller, B., Craney, J. L., Bolhofner, K., Williams, M., & Zimerman, B. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.7.1278 · Cited by 69
Managing irritability and aggression in autism spectrum disorders in children and adolescents
Robb, A. S. (2010) · Developmental Disabilities Research Reviews · doi:10.1002/ddrr.118 · Cited by 73
Autism, an extreme challenge to integrative medicine. Part 2: medical management.
Kidd, P. M. (2002) · PubMed · Cited by 101
Toren, P., Ratner, S., Laor, N., & Weizman, A. (2004) · Drug Safety · doi:10.2165/00002018-200427140-00005 · Cited by 75
de León, J., Greenlee, B., Barber, J. W., Sabaawi, M., & Singh, N. N. (2008) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2008.10.010 · Cited by 73
Characteristics of Ice Hockey–Related Injuries Treated in US Emergency Departments, 2001–2002
Hostetler, S. G., Xiang, H., & Smith, G. A. (2004) · PEDIATRICS · doi:10.1542/peds.2004-1565 · Cited by 70
What the DSM-5 Portends for Research, Diagnosis, and Treatment of Autism Spectrum Disorders
Mahjouri, S., & Lord, C. E. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0327-2 · Cited by 66
“Positive outcomes associated with pharmaceutical interventions include improvement in executive functioning and reduction in stereotypy, aggressive behaviors and irritability [59, 62].”
BackgroundDesign and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome
Neul, J. L., Percy, A. K., Benke, T. A., Berry‐Kravis, E., Glaze, D. G., Peters, S. U., Jones, N. E., & Youakim, J. M. (2022) · Contemporary Clinical Trials · doi:10.1016/j.cct.2022.106704 · Cited by 71
Dickstein, D. P., Puzia, M. E., Cushman, G. K., Weissman, A. B., Wegbreit, E., Kim, K. L., Nock, M. K., & Spirito, A. (2015) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.12385 · Cited by 62
“serve a different function (McCracken et al., 2002; Minshawi, 2008); and (3) factors that might limit participants’ understanding of the SI-IAT, including current psychotic disorder, Wechsler Abbreviated Scale of Intelligence (WASI; Psychological Corporation, 2013) full scale intelligence quotient (FSIQ) ≤70, or limit…”
BackgroundTargets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions
Lacivita, E., Perrone, R., Margari, L., & Leopoldo, M. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00965 · Cited by 78
Autism, an extreme challenge to integrative medicine. Part: 1: The knowledge base.
Kidd, P. M. (2002) · PubMed · Cited by 94
Aripiprazole in Autism Spectrum Disorders and Fragile X Syndrome
Erickson, C. A., Stigler, K. A., Posey, D. J., & McDougle, C. J. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.04.001 · Cited by 65
“As with the aripiprazole trials that were reviewed (as previously mentioned), both risperidone trials noted treatment associated improvement on the CGI-I and ABC-I during 8 weeks of treatment.(31,32) The RUPP risperidone trial and the flexibleERICKSON ET AL.”
InfluentialSelf-citationAran, A., & Cayam-Rand, D. (2020) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10386 · Cited by 65
Higashida, H., Munesue, T., Kosaka, H., Yamasue, H., Yokoyama, S., & Kikuchi, M. (2019) · Diseases · doi:10.3390/diseases7010024 · Cited by 74
“In clinical settings, there are no effective treatments for the various symptoms of ASD, except for irritability, which can be alleviated by risperidone or aripiprazole [15,16].”
BackgroundWink, L. K., Erickson, C. A., & McDougle, C. J. (2010) · Current Treatment Options in Neurology · doi:10.1007/s11940-010-0091-8 · Cited by 68
Self-citationDiffusion of efficacious interventions for children and adolescents with mental health problems
Graeff‐Martins, A. S., Flament, M. F., Fayyad, J., Tyano, S., Jensen, P., & Rohde, L. A. (2008) · Journal of Child Psychology and Psychiatry · doi:10.1111/j.1469-7610.2007.01827.x · Cited by 63
Cohen, D., Raffin, M., Canitano, R., Bodeau, N., Bonnot, O., Périsse, D., Consoli, A., & Laurent‐Levinson, C. (2012) · Research in Autism · doi:10.1016/j.rasd.2012.08.001 · Cited by 67
Sabus, A., Feinstein, J. A., Romani, P. W., Goldson, E., & Blackmer, A. B. (2019) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2238 · Cited by 67
“Mirtazapine The involvement of serotonin was implicated in SIBs due to its established role in impulsivity and aggression as well as its connection with depression and suicide.1 Due to its effect on the serotonin system, mirtazapine has been hypothesized to decrease symptoms such as aggression, irritability, and SIBs…”
MethodInfluentialSelf injurious behavior in autism: clinical aspects and treatment with risperidone
Canitano, R. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-005-0337-x · Cited by 75
Klaiman, C., Huffman, L., Masaki, L., & Elliott, G. R. (2013) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2012.0127 · Cited by 63
Pharmacotherapy to control behavioral symptoms in children with autism
Doyle, C. A., & McDougle, C. J. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.674110 · Cited by 63
“One study of risperidone in children with autism, aged 5 -- 17 years, revealed a 57% decrease in irritability as measured by the ABC-I subscale, compared with 14% in the placebo group [47].”
MethodSelf-citationAsperger syndrome and criminal behaviour
Dein, K., & Woodbury‐Smith, M. (2010) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.107.005082 · Cited by 90
Canitano, R. (2004) · Brain and Development · doi:10.1016/j.braindev.2004.06.006 · Cited by 68
Unwin, G. L., & Deb, S. (2011) · Research in Developmental Disabilities · doi:10.1016/j.ridd.2011.07.031 · Cited by 62
Effects of Risperidone in Autistic Children and Young Adults: A Systematic Review and Meta-Analysis
Mano‐Sousa, B. J., Pedrosa, A. M., Alves, B. C., Galduróz, J. C. F., Belo, V. S., Chaves, V. E., & Duarte‐Almeida, J. M. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200529151741 · Cited by 70
Drug Treatment of Epilepsy Neuropsychiatric Comorbidities in Children
Holmes, G. L. (2020) · Pediatric Drugs · doi:10.1007/s40272-020-00428-w · Cited by 67
Guía de buena práctica para el tratamiento de los trastornos del espectro autista
Biggi, J. F., Arroyo, M. J. F., Muñoz, L. B., Aguilera, E. T., Pallarés, J. A., Carmona, M. B., Yunta, J. A. M., Amaia Hervas, G., Canal‐Bedia, R., Rodríguez, J. M. H., et al. (2006) · Revista de Neurología · doi:10.33588/rn.4307.2005750 · Cited by 175
Developing Drugs for Core Social and Communication Impairment in Autism
Posey, D. J., Erickson, C. A., & McDougle, C. J. (2008) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2008.06.010 · Cited by 62
Self-citationPsychopharmacology of Autism Spectrum Disorders
Kaplan, G., & McCracken, J. T. (2012) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2011.10.005 · Cited by 71
Self-citationMohammadi, M.-R., Yadegari, N., Hassanzadeh, E., Farokhnia, M., Yekehtaz, H., Mirshafiee, O., & Akhondzadeh, S. (2013) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3182a9339d · Cited by 61
Yang, Y. J. D., Sukhodolsky, D. G., Lei, J., Dayan, E., Pelphrey, K. A., & Ventola, P. (2017) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-017-9183-z · Cited by 57
“Currently, the Food and Drug Administration (FDA) has approved two atypical antipsychotic drugs for treating irritability and disruptive behavior associated with autism: risperidone [78, 79] and aripiprazole [80, 81].”
BackgroundGencer, Ö., Emiroglu, F. N. I., Miral, S., Baykara, B., Baykara, A., & Dırık, E. (2007) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-007-0656-6 · Cited by 70
“It has been widely used in drug treatment studies in children and adolescent with autism [6, 26, 34].”
BackgroundMethodInfluentialDoey, T., Handelman, K., Seabrook, J. A., & Steele, M. M. (2007) · The Canadian Journal of Psychiatry · doi:10.1177/070674370705200605 · Cited by 62
Prolactin Release in Children Treated With Risperidone
Troost, P. W., Lahuis, B., Hermans, M. H. A., Buitelaar, J. K., van Engeland, H., Scahill, L. D., Minderaa, R. B., & Hoekstra, P. J. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31802e68d5 · Cited by 61
Self-citationPharmacologic Treatment for the Core Deficits and Associated Symptoms of Autism in Children
West, L., Waldrop, J. B., & Brunssen, S. (2009) · Journal of Pediatric Health Care · doi:10.1016/j.pedhc.2008.12.001 · Cited by 72
Nurmi, E. L., Spilman, S. L., Whelan, F., Scahill, L., Aman, M. G., McDougle, C. J., Arnold, L. E., Handen, B. L., Johnson, C. R., Sukhodolsky, D. G., et al. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.26 · Cited by 67
“disorder, pervasive developmental disorder not otherwise specified) accompanied by severe irritability (aggression, tantrums, and/or self-injurious behaviors) defined by a score ofX18 on the Aberrant Behavior Checklist Irritability subscale were treated for 8 weeks with risperidone or placebo as part of two controlled…”
BackgroundMethodSelf-citationEffects of risperidone on glutamate receptor subtypes in developing rat brain
Choi, Y. K., Gardner, M. P., & Tarazi, F. I. (2009) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2008.08.010 · Cited by 62
An Open-Label Trial of Risperidone in Children and Adolescents with Severe Mood Dysregulation
Krieger, F., Pheula, G. F., Coelho, R. P. S., Zeni, T. A., Tramontina, S., Zeni, C., & Rohde, L. A. (2011) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0123 · Cited by 70
“The approved indication was based on trials in patients with pervasive developmental disorders (PDDs) (Aman et al. 2002; McCracken et al. 2002; Reyes et al. 2006; Pandina et al. 2007).”
Public Health Literature Review of Fragile X Syndrome
Raspa, M., Wheeler, A., & Riley, C. M. (2017) · PEDIATRICS · doi:10.1542/peds.2016-1159c · Cited by 75
Stepanova, E. A., Dowling, S., Phelps, M., & Findling, R. L. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.4/rfindling · Cited by 66
Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial
DeVane, C. L., Charles, J. M., Abramson, R. K., Williams, J. E., Carpenter, L. A., Raven, S., Gwynette, F., Stuck, C. A., Geesey, M. E., Bradley, C., et al. (2019) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2271 · Cited by 60
“(Pharmacotherapy 2019;39(6):626–635) doi: 10.”
Pharmacological management of core and comorbid symptoms in autism-spectrum disorder
Elvins, R., & Green, J. (2010) · Advances in Psychiatric Treatment · doi:10.1192/apt.bp.108.005538 · Cited by 62
Pharmacotherapy of Irritability in Pervasive Developmental Disorders
Stigler, K. A., & McDougle, C. J. (2008) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2008.06.002 · Cited by 64
Self-citation
Metadata
- Authors
- McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., McDougle, C. J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N. M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., & McMahon, D.
- Affiliations
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-08
- Volume
- 347
- Issue
- 5
- Pages
- 314-321
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1968430210
- Cited by
- 1,574
- References
- 25
- Citations by year
- 2026: 50 · 2025: 68 · 2024: 54 · 2023: 43 · 2022: 51 · 2021: 77 · 2020: 54 · 2019: 43 · 2018: 69 · 2017: 56 · 2016: 57 · 2015: 59 · 2014: 57 · 2013: 88 · 2012: 88
- FWCI
- 30.55
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- National Institutes of Health (n01mh070009-000, n01mh070001-008, n01mh070010-001, n01mh080011-005)
- National Institute of Mental Health (N01-MH-80011, N01 MH 70010, K23MH001883, N01 MH-70001, N01 MH 70009)
- National Center for Research Resources (M01-RR 00750, M01 RR-00052, M01-RR-00034, M01RR000750, M01RR000052, M01RR000034)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
- Keywords
- risperidone, autism spectrum disorder, atypical antipsychotics, irritability, tantrums, aggression, self-harm, Aberrant Behavior Checklist, weight gain, adverse effects, children
- MeSH terms
- Adolescent, Autistic Disorder, Child, Child Behavior, Child, Preschool, Double-Blind Method, Female, Humans, Male, Antipsychotic Agents, Treatment Outcome, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.